Nyrada (ASX: NYR) — Company Overview, News & Financial Data
Nyrada is a preclinical-stage drug development company specializing in the discovery and development of novel small molecule therapeutics for cardiovascular, neurodegenerative, and chronic inflammatory conditions.
Nyrada
Nyrada is a preclinical-stage drug development company specializing in the discovery and development of novel small molecule therapeutics for cardiovascular, neurodegenerative, and chronic inflammatory conditions. The company focuses on developing TRPC ion channel inhibitors and target-specific small molecules based around a benzopyran molecular scaffold to treat areas of significant unmet clinical need. Its primary research and development pipeline targets myocardial ischemia and arrhythmia control, stroke, traumatic brain injury, and autoimmune diseases. Through early-stage drug development and preclinical studies, Nyrada aims to advance targeted therapies where few effective treatment options currently exist.
Snapshot
Operations
Products and/or services of Nyrada
- Cardioprotection Program: Preclinical development of small molecule therapeutics targeting myocardial ischemia and arrhythmia control, aiming to minimize cardiac tissue damage and manage heart rhythm disruptions during acute cardiac ischemic events in cardiovascular patients.
- Stroke Neuroprotection: Preclinical drug development program targeting acute ischemic stroke to limit secondary neuronal cell loss, minimize neuroinflammation, and reduce long-term neurological disability in adult patients following ischemic brain injuries.
- Traumatic Brain Injury Therapeutics: Preclinical neuroprotectant drug development focused on treating acute traumatic brain injury to mitigate secondary brain damage, decrease cerebral tissue swelling, and improve long-term functional recovery following head trauma.
- PCSK9 Inhibitor Development: Cardiovascular drug candidate designed as a novel small molecule inhibitor of PCSK9 to lower elevated blood LDL-cholesterol levels in hypercholesterolemia patients who are intolerant of or non-responsive to statins.
- TRPC Ion Channel Inhibitors: Discovery and preclinical development of novel small molecule TRPC ion channel inhibitors engineered to regulate intracellular calcium entry, mitigating tissue necrosis and cellular degeneration across neurodegenerative and cardiovascular diseases.
- Autoimmune and Inflammatory Therapeutics: Preclinical drug discovery targeting chronic inflammatory conditions and autoimmune diseases, focusing on novel small molecules targeting TRPC ion channels and inflammatory pathways to manage peripheral nerve pain and psoriasis.
Nyrada executive team
- James BonnarCEO, MD & Director
- Cameron Peter JonesChief Financial Officer
- Benjamin EvisonChief Scientific Officer
- Dimitri BurshteinInvestor Relations Manager
- Mark WaringSenior Vice President of US Operations
- David James FranksCompany Secretary
- Jasneet ParmarDirector of Research & Development
- Alex SuchowerskaDirector of Clinical Development & Regulatory Affairs
Latest news about Nyrada
Nyrada raises $12M through placement
AustraliaNyrada reports $8.4M cash in annual results
AustraliaNyrada secures key US patent for Xolatryp
AustraliaNyrada activates first site for Phase 2a trial
AustraliaNyrada advances Xolatryp following positive Phase 1 results
AustraliaNyrada cleared to start Phase 2a heart attack trial of Xolatryp
Australia
Recent announcements
What Nyrada (NYR) has told the market, newest first.
- Nyrada Receives Positive FDA FeedbackPrice sensitive
- Attaching Options ProspectusPrice sensitive
- Securities Purchase Plan Offer Booklet
- 2026 AGM Letter to Shareholders, Notice of Meeting & Proxy
- Nyrada US Patent for Xolatryp Granted
- Cleansing Statement
- Application for quotation of securities - NYR
Key financials
Reported results for Nyrada, in AUD.
- Market cap
- 117.7M
- Revenue (TTM)
- 2M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.0
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| — | -8.6M | -6.5M | |
| 2.4M | -9.2M | -4.8M | |
| 3.2M | -4.6M | -1.4M | |
| 1.4M | -14.1M | -7.8M |